Last updated: 2026-09-09 05:11:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Syndax Pharmaceuticals, Inc. (SNDX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $19.93, with a market capitalization of $1.84B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12.99 to $25.59. This page covers its latest market performance, valuation, price trends and company information.
$1.84B | |
$20.19 | |
$29.86 | |
$3.39 | |
$20.56 | |
977.24K | |
1.69M | |
-- | |
$25.59 | |
$12.99 | |
-- | |
-- |
Syndax Pharmaceuticals, Inc. (SNDX) last closed at $20.56 as of 2026-09-08 23:31:00, unchanged from the previous close of $20.56.
During the latest regular trading session, SNDX traded between $3.39 and $29.86, with a volume of 977.24K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Syndax Pharmaceuticals, Inc. (SNDX) moved from $20.16 to $19.93, representing a decline of 1.12% ($0.23).
The stock traded between $19.00 and $21.00 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 1.40 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 55.1%
SNDX is currently trading at $19.93, placing it 55.1% of the way from its 52-week low of $12.99 to its 52-week high of $25.59. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 298 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Syndax Pharmaceuticals, Inc. (SNDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.